in 10 risk of intestinal lymphoma in a newly diagnosed patient with coeliac disease.'0 Exactly how and why coeliac disease is associated with an increased risk of lymphomatous and carcinomatous change remains unknown. Several explanations have been put forward. The mucosal damage in coeliac disease may make the small intestine more permeable to environmental carcinogens which, with associated malabsorptive vitamin A deficiency and increased vulnerability to oxidative injury, would enhance carcinogenic change. Known predisposing factors for the development of small intestinal adenocarcinoma include Crohn's disease, adenomatous polyps and Peutz-Jeugher's syndrome.4 Perzin et al" reported that 23 of 51 cases of small intestinal adenocarcinoma had evidence of adenoma and carcinoma in the same lesion. Survival is dependent on the presence or absence of nodal involvement at presentation. Five year survival with node negative disease is 68%, while the overall figure varies from 15 to 20%.12 Thus, as the prognosis is not uniformly poor and some patients are potentially curable by total resection (as in patient 2 in the present paper), limiting postoperative morbidity and recognising potential complications becomes very important. Clinically unmasked coeliac disease complicating Whipple's resection has not been described before and these two cases illustrate the importance of early diagnosis and dietary intervention prior to surgery. Previous cases of failure to thrive and weight loss following Whipple's resection may be simply put down to the effects of small bowel resection, pancreatic insufficiency, tumour progression, or early recurrence. Underlying coeliac disease should also be considered and the tumour-free mucosal margins carefully inspected. tumour of the uterus is reported. The patient presented with postmenopausal bleeding and subsequently underwent total hysterectomy and bilateral salpingooophorectomy. Sections of the tumour showed a low grade endometrial stromal sarcoma coexisting with areas consistent with high grade sarcoma. The sarcoma cells, in both the low and high grade areas, were positive for vimentin and negative for desmin and cytokeratin on immunohistochemistry. While the sarcoma cells in the low grade region showed immunoreactivity for oestrogen and progestogen receptors, those in the high grade region did not. Using chromosome in situ hybridisation, the low grade portion of the sarcoma was diploid for chromosomes X, 11, 12 , and 17, whereas the more anaplastic areas were aneuploid for these chromosomes. This case may represent an example of high grade endometrial stromal sarcoma arising by dedifferentiation from a low grade stromal sarcoma. Adequate sampling is important in identifying such anaplastic changes as the origin of the tumour will affect patient management. , oestrogen receptor (Dako), and proneoplasms, including gestogen receptor (Abbott Laboratories, UK). low and high grade Paraffin wax sections were pretreated in a different architectural microwave oven (Bio-Rad H2500, USA) bes and clinical behav-fore being stained for oestrogen and prowith respect to their gestogen receptors. Here, we report a case
The tumour cells in both the low and high romal sarcoma coexist-grade regions were positive for vimentin but arising from, adjacent negative for the cytokeratins and desmin, supstromal sarcoma. Un-porting the histological diagnosis of endome-3tumour dedifferentia-trial stromal sarcoma. The low grade portion of )rted in uterine stromal the sarcoma showed immunoreactivity for both ive studies of steroid oestrogen and progestogen receptors while the ession and cytogenetic high grade sarcoma was negative for both horlescribed previously in mone receptors. Figure 3 Multiple in situ hybridisation signals were observed in the high grade sarco after hybridisation with a DNA probe specific for chromosome 12 (arrows). ture Collection, USA), and the X chromos (pBamX5) (generous gift from Dr AHN ] man) were labelled with biotin via nick tra tion (Boehringer, USA). Immunohistoche try was carried out using avidin, biotiny mouse anti-avidin, rabbit anti-mouse pe dase, and 3,3'-diaminobenzidine (Dako,: Wycombe, UK) to visualise peroxidase act The slides were then counterstained with matoxylin and mounted.
At least 500 nuclei were assessed in the grade and high grade portions of the sarc The number of chromosome specific in hybridisation signals was evaluated as scribed previously.6 7 Uterine smooth m cells present in the tissue sections acted a internal control for normal diploid XX ce In areas of low grade sarcoma, less than of the cells had more than two copies of mosomes X, 11, 12, and 17 (fig 2) . In con over 60% of cells in areas of high sarcoma contained more than two copi these four chromosomes. Some cells contE up to eight or nine signals (fig 3) .
Discussion
Dedifferentiation is a well recognised phei enon in bone and soft tissue tumours, wh high grade tumour coexists with a relal low grade and well differentiated malii tumour of the same origin. It is regarded histological indicator of tumour progre when a low grade tumour transforms ii poorly differentiated and more malit umour.3 However, dedifferentiation has I been described in uterine stromal sarc Review of literature revealed that only cases of coexisting low grade and high j uterine stromal sarcomas have been ported.4 5 Two cases of high grade stroma coma have been reported, one arising fror sarcomatous overgrowth of a low grade n rian adenosarcoma and the other follc radiotherapy for low grade endometrial mal sarcoma. 9 Details of oestrogen and gestogen receptor expression and the k type in these cases were not given. In the reported here, the uterine tumour was a low grade stromal sarcoma, with transition to high s%. grade stromal sarcoma at the peripheral portion of the tumour lining the endometrium. Immunoreactivity for both oestrogen and progesterone receptors was noted in the part of the tumour with appearances histologically diagnostic of low grade stromal sarcoma. Thẽ high grade tumour was negative for both *FF steroid hormone receptors. This is consistent with previous immunohistochemical studies by other investigators.'0 Such differential expression of hormone receptors may explain differences in response to hormone therapy. It has been reported that complete or partial resolution of recurrent or metastatic low grade stromal sarcoma can occur after treatment with progestogens.' 2 4 These reports have led to the recommendation that women with low grade stromal sarcoma should be treated by total ma abdominal hysterectomy and bilateral salpingo-oophorectomy followed by long term progestogen therapy. Alternative treatment some such as radiotherapy should only be considered 1oPfor women whose neoplasms do not contain nslasignificant amounts of progestogen receptors "misor are resistant to progestogens. Progestogens The suitability of measuring the S-phase fraction in human breast cancer by labelling tumour cells from fine needle aspirates (FNAs) in vitro with iododeoxyuridine (IdU) was studied in 11 patients. The S-phase fraction was measured both in preoperative FNAs labelled in vitro with IdU, and in FNAs taken from the same tumour when surgically removed after intravenous administration ofIdU. Frozen sections were also immunostained for incorporated IdU. The mean S-phase fraction measured in FNAs after in vitro or in vivo labelling and in sections after in vivo labelling was 4.0, 3.6, and 3.1, respectively. Results of in vitro and in vivo labelling of FNAs with IdU were similar. However, as the S-phase fraction in breast cancer is generally low, the variation between the different measurements is too large; therefore, the S-phase fraction is not a suitable indicator of response to treatment. Decreasing proliferative activity in tumours could be used as an early indication ofresponse to systemic treatment. Changes in S-phase fraction as a measure of the proliferative activity could be monitored in sequentially obtained fine needle aspirates (FNAs). Immunostaining of iododeoxyuridine (IdU) incorporated into the DNA in the S-phase of the cell cycle offers a sensitive and specific method to assess S-phase fraction in FNAs from breast tumours. In vivo labelling of tumour cells requires the intravenous administration of IdU. Apart from the discomfort to the patient and costs involved, IdU administration may in turn cause further mutation. Moreover, the optimal timing of IdU administration varies from patient to patient. In vitro labelling with IdU is an attractive alternative.
Methods idu LABELLING
The S-phase fraction was measured in 17 patients with primary breast cancer. FNAs were taken from the primary breast carcinomas on the day before surgical removal of the tumour. Viable carcinoma cells were counted using the trypan blue exclusion test. The tumour cells were labelled in vitro by being incubated at 37°C for two hours in DMEM culture medium (Gibco BRL, Breda, The Netherlands) containing 10% fetal calf serum (Gibco BRL) and 10 jiM IdU (Sigma, Axel, The Netherlands). Approximately six hours before surgery the patients received an intravenous infusion of 100 mg IdU in 50 ml. Directly after surgical removal of the tumour a second FNA was taken for the analysis of in vivo labelling. FNAs were washed in phosphate buffered saline (PBS), resuspended in 70% alcohol and stored at 4°C pending analysis. Tumour tissue was snap frozen in liquid nitrogen until further processing.
Permission to administer IdU was obtained from the Medical Ethical Committee of the Antoni van Leeuwenhoekhuis. Informed consent was obtained from each patient.
IMMUNOCYTOCHEMICAL STAINING FOR idu
Cytospin preparations were prepared, dried and washed in PBS. After being washed in PBS, frozen tumour sections were treated in the same way as the cytospin preparations. All samples were incubated in 95% formamide in PBS at 70°C for 45 minutes, washed three times for five minutes in 0.1 M Tris/HCl (pH 7.6) supplemented with 5% Tween 20, followed by a 10 minute wash in Tris/HCl (pH 7.6). After preincubation for 15 minutes in PBS supplemented with 0.5% Tween 20, 0.1% bovine serum albumin (BSA) and 10% normal rabbit serum, the preparations were incubated at room temperature with anti-IdU murine
